- Home
- EROC vs ABCL Comparison
EROC vs ABCL Comparison
Compare EROC & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EROC | ABCL |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.1B |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EROC | ABCL |
|---|---|---|
| Price | $8.22 | $12.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $22.13 | $17.17 |
| AVG Volume (30 Days) | 2.9M | ★ 4.3M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $146.63 | N/A |
| Revenue Next Year | $214.16 | $7.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $7.65 | $2.75 |
| 52 Week High | $17.98 | $14.98 |
Technical Indicators
Market Signals| Indicator | EROC | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 48.43 |
| Support Level | $7.65 | $11.78 |
| Resistance Level | $14.06 | $12.88 |
| Average True Range (ATR) | 0.80 | 0.83 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 12.39 | 40.11 |
Price Performance
Historical ComparisonAbout ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.